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Abstract
Chronic pain represents an immense clinical problem. With tens of millions of people in the 
United States alone suffering from the burden of debilitating chronic pain, there is a moral 
obligation to reduce this burden by improving the understanding of pain and treatment 
mechanisms, developing new therapies, optimizing and testing existing therapies, and improving 
access to evidence-based pain care. Here, we present a goal-oriented research agenda describing 
the American Pain Society’s vision for pain research aimed at tackling the most pressing issues in 
the field.
Perspective—This article presents the American Pain Society’s view of some of the most 
important research questions that need to be addressed to advance pain science and to improve 
care of patients with chronic pain.
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The Disease of Chronic Pain and the Desperate Status of Pain Research in 
America
Chronic pain refers to multiple clinical conditions defined by longstanding pain that 
adversely impact quality of life. Common chronic pain conditions include, but are not 
limited to, low back pain, headache conditions (eg, migraine and tension-type headache), 
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osteoarthritis, temporomandibular disorders, irritable bowel syndrome, chronic widespread 
pain, and neuropathic pain conditions (eg, diabetic neuropathy, postherpetic neuralgia). 
Although historically conceptualized as distinct disorders whose only common feature was 
persistent pain, increasing evidence suggests that many chronic pain conditions may share 
some underlying pathophysiologic mechanisms. Specifically, altered neurologic function 
resulting in aberrant processing of somatosensory information and leading to comorbid 
symptoms and syndromes has been documented in numerous chronic pain conditions, 
including alterations in peripheral nociceptor activity as well as brain structure and 
function.22,84 Thus, a recent Institute of Medicine (IOM) report stated, “Chronic pain can be 
a disease in itself. Chronic pain has a distinct pathology, causing changes throughout the 
nervous system that often worsen over time. It has significant psychological and cognitive 
correlates and can constitute a serious, separate disease entity” (p. 3).50 Moreover, chronic 
pain represents the most prevalent, disabling, and expensive public health condition in the 
United States, affecting more than 100 million people in the United States, with annual costs 
to society estimated at $635 billion.38,50 This exceeds the combined costs of cancer, heart 
disease, and diabetes38 (Table 1). Further, low back pain is the leading cause of years lived 
with disability, and chronic pain conditions comprise 3 of the top 5 conditions producing the 
greatest years lived with disability in the United States.94
Importantly, although chronic pain affects individuals of all ages, races, and genders, it 
disproportionately impacts members of vulnerable population groups. Indeed, women are at 
substantially greater risk for multiple chronic pain disorders compared to men,31,68 and the 
prevalence and impact of chronic pain is greater in older adults.37,44 Racial and ethnic 
disparities in chronic pain have also been reported, with members of minority groups at 
increased risk for more severe pain and disability as well as for undertreatment of their 
pain.3,41 Lastly, historically pain in young children has often gone undertreated, which can 
cause altered neurologic function, placing individuals at potentially increased risk of chronic 
pain later in life.7,97
Despite its enormous societal impact, we have not seen advancements in treatment of 
chronic pain that reduce its burden in the population.63,64 Although there are multiple 
explanations for this limited progress, the clearest and most direct path to achieving 
dramatic advances in pain treatment is through substantially increased investment in pain 
research and education funding, which would enable the pursuit of an aggressive 
translational pain research agenda (described below). Although the National Institutes of 
Health (NIH) reports that pain research expenditures have increased in recent years,72 
independent analyses of NIH data showed decrements in funding for pain research from 
2003 to 2007.10 Even the most optimistic estimates indicate that pain research is woefully 
underfunded relative to its public health impact. Based on information provided by the 
NIH,72 pain research expenditures in 2012 totaled $396 million, approximately 1.2% of the 
NIH budget. To put this into perspective, NIH expenditures for several health conditions, 
relative to their societal costs and population prevalence in the United States, are depicted in 
Table 2 and Fig 1. Moreover, chronic pain represents a major health concern among 
members of the active duty military and veterans. However, the Department of Defense ($21 
million) and the Department of Veterans Affairs ($13.4 million) also allocate a very small 
percentage of their research budgets to pain research.51 These data show that compared to 
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other disease conditions, chronic pain is substantially underfunded relative to its prevalence, 
disease burden, and economic toll.
The limited funding allocated for pain research has hampered clinicians’ ability to provide 
optimal, evidence-based care to individuals suffering from chronic pain. In addition to the 
relative lack of newly developed pain treatments, the inadequacy of available information 
regarding the long-term safety and effectiveness of existing treatments has hampered 
evidence-based pain treatment. Indeed, the dramatic increase in the prescription of opioids 
over the last 2 decades emerged in the context of limited availability of alternative 
treatments and insufficient data regarding the long-term safety and efficacy of long-term 
opioid therapy for chronic pain.
The American Pain Society (APS) continues to advocate for increased pain research 
funding, and an important complement to these advocacy efforts is a vision for where pain 
research should go in the future—a pain research agenda for the 21st century, which we 
present in this article. The idea for this APS pain research agenda germinated with the 
release of the IOM report on chronic pain some 3 years ago. Because the APS mission 
focuses on interdisciplinary research and evidence-based pain care, the APS President and 
Board of Directors decided that development and publication of the APS Research Agenda 
was both important and timely given the ongoing activities related to pain research at the 
national level (ie, the work of the Interagency Pain Research Coordinating Committee). 
Authors were chosen from the APS Board of Directors and the APS membership, and the 
authorship team was selected to ensure representation from multiple professional disciplines 
and included expertise in clinical, translational, and basic science research as well as 
educational and health policy research. Rather than a topical or method-based approach, we 
propose a goal-oriented research agenda, which emphasizes important outcomes that need to 
be achieved in order to advance pain treatment. The proposed goals include a mix of 
intermediate (Goals 3–5) and long-term (Goals 1 and 2) initiatives, attainment of which has 
the potential to transform pain management. The focus of this research agenda is on chronic 
rather than acute pain, although many of the proposed goals are of relevance to both. 
Specifically, the APS Pain Research Agenda identifies 5 broad goals:
1. Develop novel pain treatments that enhance clinically meaningful pain relief and 
functional improvement with acceptable adverse effects.
2. Expedite progress toward the prevention, diagnosis, and management of chronic 
pain conditions.
3. Optimize the use of and access to currently available treatments that are known to 
be effective.
4. Understand the impact of health policies and systems on pain treatment.
5. Improve pain management through education research.
Within each goal, several lines of research that would help fulfill the goal are discussed. 
However, this is not meant to be a comprehensive overview of important research topics. 
Instead, the intended focus of the research agenda is on achieving the proposed goals 
through outstanding science that covers the entire translational spectrum. The article 
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concludes by discussing potential barriers to transformative pain research and discusses 
potential solutions.
A Goal-Oriented Agenda for Pain Research
Goal 1: Develop Novel Pain Treatments That Enhance Clinically Meaningful Pain Relief and 
Functional Improvement With Acceptable Adverse Effects
Although clinical implementation of novel treatments represents a long-term enterprise, 
short-term and intermediate-term progress toward this goal is attainable in the form of 
discovery of potential new targets and therapies and translating these discoveries into 
humans. In the past 3 decades, physiologic and pharmacologic pain research has produced 
enormous advances in our understanding of 1) the basic transduction mechanisms that 
activate pain-sensing neurons (nociceptors) and propagate this information centrally, 2) the 
molecular mechanisms that drive plasticity in the nervous system promoting the 
development and maintenance of chronic pain states, and 3) the pharmacology of 
endogenous circuits that negatively and positively regulate pain. This research has led to 3 
paths of therapeutic development for pain: interventions targeted at blocking the 
transduction of pain signals at their peripheral source or along the nociceptor, therapeutics 
that disrupt or reverse molecular mechanisms of plasticity that are thought to underlie pain 
plasticity, and therapeutics that modulate or mimic endogenous pain control mechanisms. 
All 3 of these approaches have been successful in bringing new pain therapeutics either to 
market or at least to clinical trials. Examples include TRPV1 antagonists (transduction 
blocker), which have been verified to block thermal hyperalgesia in humans15; nerve growth 
factor–sequestering treatments (plasticity modulator), which have shown remarkable 
efficacy in a variety of chronic pain conditions11,54,57,59; and norepinephrine reuptake 
inhibitors (endogenous pain modulation enhancer), which have been particularly successful 
for neuropathic pain.75,100 Although some of these treatments may not gain regulatory 
approval because of adverse side effects,40,54 these represent powerful examples of the 
utility of physiologic and pharmacologic pain research for bringing new, mechanism-based 
approaches forward for clinical development for the treatment of clinical pain disorders.
Recent advances have also occurred in nonpharmacologic treatments that activate 
endogenous pain modulatory systems, with minimal adverse effects. For example, 
transcranial magnetic stimulation and direct current stimulation provide noninvasive 
methods for altering central pain processing, and some evidence suggests potential efficacy 
in ameliorating acute and chronic pain.71,73 Further, emerging psychological approaches 
such as neurofeedback offer the possibility of training patients to directly control their own 
pain modulatory processes.14,52
Despite these successes, research investment in basic pain research in academia is falling, 
and biotechnology and pharmaceutical industrial support for pain research has decreased 
dramatically in terms of dollars and jobs since the financial collapse of 2007.82,88 Why has 
this happened? There are fiscal and governmental policy issues that unquestionably have 
played an important role; however, a negative outlook on the therapeutic development for 
chronic pain has undoubtedly taken hold in some circles8,90 (for an opposing view, see69). 
Despite this, a recent survey of neurologists found that the most transformative drug of the 
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past decade was the triptan class because of its profound impact on the treatment of the 
world’s most common neurologic disorder, migraine headache.55 It should be noted that this 
family of drugs was identified via rationally designed preclinical studies searching for 
compounds with a specific mechanism and represents a clear success in translating 
hypotheses into humans. We argue that there is every reason for an optimistic outlook in 
terms of future therapeutic development for the pain and analgesia area. However, this 
opportunity cannot be seized without investment from both the public and private sectors 
and innovation from within the pain research community. The problem of chronic pain is 
accelerating in developed countries as their populations age and the burden of chronic 
disease continues to grow.50 We propose the following priorities for continuing to build on 
the dramatic growth in knowledge of basic mechanisms of pain and pain plasticity to find 
novel therapeutics that will alleviate suffering brought about by chronic pain.
Discovery Research Is the Foundation for Development of Novel Pain 
Therapies—Physiologic and pharmacologic research into pain transduction and plasticity 
has led to the elucidation of countless targets for potential therapeutic development.101 For 
instance, the pain gene database contains at least 390 distinct genes encompassing transgenic 
mice that have a nociceptive phenotype.58 The large number of receptors, channels, 
signaling molecules, and other proteins identified as potential pain therapeutic targets is not 
surprising given what we know from clinical experience: chronic pain is a tremendously 
complex set of conditions, and the many forms of chronic pain do not all involve the same 
underlying mechanism(s). Thus, physiologic and pharmacologic discovery research—the 
identification of potential targets for the development of novel analgesics—must continue. 
The large number of potential pain therapeutic targets may seem overwhelming, but we are 
only now beginning to gain the technical capacity to look at how these targets integrate to 
form complex physiology and how basic studies in model organisms can be combined with 
rapid advances in human genetics and imaging to develop and validate targets.
The foundation for therapeutic interventions can be laid by basic science advances that 
elucidate the fundamental biology of pain and its development into the chronic pain disease 
state. This includes basic science research conducted in animals and in humans and can 
range from discovery of neurotransmitters, receptors, and underlying mechanisms, to genetic 
discovery studies, to brain imaging research designed to further elucidate the central 
processing of acute and chronic pain. We must increase efforts to identify new targets for 
the development of novel pain therapies, and further we must increase our focus on 
conducting proof-of-concept studies in humans. Importantly, novel targets (as referred to 
throughout this article) include not only molecular mechanisms but also peripheral tissues, 
central nervous system structures and pathways, and behavioral and psychosocial processes. 
This will necessitate financial support for such studies.
Augmenting and/or Optimizing Existing Treatments Can Lead to Development 
of New Therapeutics—Innovation in pain research need not rely solely on novel target 
development. Multimodal analgesia is commonly employed in primary care and in 
specialized pain clinics throughout the world, and the rapid proliferation of medical devices 
has opened up new horizons in pain therapeutics. Basic pharmacology has long been a 
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stronghold of research in the pain area, and some of the most highly cited studies in the area 
involve the elucidation of synergistic drug interactions (eg, spinal α2-adrenergic receptors 
and mu-opioid receptors76). The discovery of a new target for pain does not have to mean 
the instigation of a decade-long drug discovery program. In some cases, clinically available 
drugs may already exist that are utilized in completely different disease areas. The pain 
research community should prioritize trials to identify and validate new pharmacotherapies.
Patients are often managed not only with multiple pharmaceutical agents but also with 
multiple nonpharmacologic therapies. Research into medical device utilization, such as 
spinal cord and peripheral nerve stimulators and/or transcranial magnetic stimulation, is 
demonstrating that important pain targets can be engaged without drug administration. 
Research into physical activity, exercise, and cognitive therapies shows that these therapies 
can be as effective as pharmaceutical therapies and can modify pain processing. Similarly, 
complementary and alternative medicine therapies are used by a large proportion of 
individuals with pain, and the quantity and quality of research on effectiveness and 
mechanisms of complementary and alternative medicine have grown exponentially in recent 
years. As our knowledge continues to grow in this area, opportunities for combining 
nonpharmacologic and pharmacologic therapies are sure to emerge. Thus, discovering 
interactions between a variety of treatments, positive and negative, and predictors of what 
makes treatments successful or unsuccessful is important in advancing and optimizing 
existing treatments.
Bidirectional Translational Research Will Improve Development of Models and 
Targets—Much has been made in recent years of the degree to which animal models are or 
are not predictive of the ability of a given therapy to effectively treat pain in humans.8,69,90 
Despite notable failures in translation (which occur in all fields of biomedicine),20,29,47 there 
have indeed been successes.54,85 Translational research should be bidirectional, with basic 
science informing clinical pain research concerning mechanisms of treatment effects, and 
clinical practice and research providing the clinical questions and definitive determinations 
of patient benefit. Thus, basic science and clinical research on pain must move to align 
preclinical and clinical study design by exploiting “translational bridges,” which represent 
opportunities to ask similar questions in clinical and preclinical studies. For example, 
preclinical studies typically assess measures of sensitization that are easily accessible in 
animal models (hypersensitivity to touch, heat, cold), whereas clinical studies ask patients 
how they feel. Notable recent efforts have been made to develop novel animal model 
outcome measures toward accessing the “degree of pain an animal feels” or the impact of 
pain on function (as opposed to sensitization).19,56,60 Similarly, the use of quantitative 
sensory testing (similar to hypersensitivity measures in animals) in clinical studies is still 
relatively rare, but incorporating quantitative sensory testing into clinical studies may 
facilitate reverse translation of findings from clinical studies to preclinical research, 
particularly when animal studies employ more sophisticated measures that do not rely 
exclusively on reflexes.
Translational pain research must incorporate a direct examination of the similarities and 
differences in the anatomy and physiology of the animals being used in preclinical studies 
relative to that of humans. The concept of using animal models of pain is predicated on the 
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assumption that there is congruency in mechanisms and the models are predictive of 
treatment effectiveness between animal models and humans. Unfortunately, these 
assumptions are not commonly tested directly, although there are some innovative 
examples.2,21,95 Determining cross-species similarity in the expression and function of pain-
related biopsychosocial processes should be a major goal of preclinical pain research.
Another key area for bidirectional translation is genetics. Advances in human genetic 
profiling have led to the identification and validation of numerous targets for pain,25,33,102 
with some of the most rapid advancements occurring in the migraine and headache fields.4 
Similarly, the rapid development of brain imaging approaches is elucidating the central 
nervous system pathways and networks involved in the experience of chronic pain and its 
successful treatment, and imaging represents another opportunity for bidirectional 
translation.61 These developments, however, cannot reach their full potential without 
translation back into preclinical models for elucidation of underlying mechanisms. Moving 
ahead, increasing bidirectional translational research has the potential to catalyze new target 
development and the refinement of pain models for both preclinical and clinical research.
Clinical Trials Should Be Fast Tracked to Advance or Eliminate Targets—The 
proliferation of potential targets to treat pain demands a concerted effort to test the 
hypotheses posed by these targets in humans. The pain research community needs to work 
collaboratively in the preclinical and clinical arenas to foster a culture promoting rapid 
translation of promising discoveries into clinical trials. Although this is not a call for 
compromises on patient safety, stakeholders must recognize that chronic intractable pain has 
a profound negative impact on quality of life and is one of the most frequent causes of 
disability and of proliferation of other severe health problems.50 Hence, there is a strong 
rationale for moving rapidly and decisively toward the testing of new mechanisms and 
therapies in humans either through repurposing existing pharmacologic and non-
pharmacologic therapeutics or through efforts to develop novel treatments. As a community, 
we must also advocate for widespread dissemination of clinical trial results, including 
negative results,78 to ensure that clinical management of pain is based on the available 
evidence. Finally, the pain research community must be willing to abandon certain targets 
when efforts in that area do not lead to clinically meaningful endpoints in humans. 
Demanding the resources for research that the chronic pain problem requires must be 
accompanied by a spirit of agile innovation in the pain research community to make 
advances for the patients we ultimately serve.
Goal 2: Expedite Progress Toward the Prevention, Diagnosis, and Management of Chronic 
Pain Conditions
Over the last several decades, both basic and clinical pain researchers have significantly 
advanced our understanding of the underlying biopsychosocial processes and risk 
determinants that contribute to chronic pain conditions. Importantly, the conceptual model 
that best incorporates existing evidence regarding risk for developing common complex 
persistent pain conditions is the biopsychosocial model,28,39 which posits that a mosaic of 
biological, psychological, and social factors represent the pathways of vulnerability to a 
variety of chronic pain conditions. The identification of the biological, psychological, social, 
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and associated molecular pathways that contribute to the onset and persistence of chronic 
pain conditions is needed if advances in the prevention, diagnosis, and management of 
chronic pain conditions are to occur. Our understanding of the peripheral, spinal, and 
supraspinal processes that contribute to chronic pain conditions has been enabled by 
advances in the quantitative and qualitative clinical phenotyping of chronic pain patients 
using validated methods that assess putative psychosocial and neurobiological risk 
determinants for chronic pain conditions. In parallel, substantial advances in genomics, 
proteomics, and bioinformatics now permit the pain research community to identify 
molecular pathways associated with the complex biopsychosocial phenotypes commonly 
observed across multiple most chronic pain conditions. These mechanistic studies need to be 
guided by large population-based epidemiologic studies that identify the biological, 
psychological, and social risk factors for the onset and maintenance of chronic pain 
conditions. Further, these epidemiologic approaches can enhance clinical trial design by 
enabling stratification of patients into subpopulations based on biopsychosocial 
characteristics, moving the field closer to personalized pain treatment (see12). This will 
increase the availability and efficacy of current and new therapies for chronic pain 
conditions.24 Despite the formidable challenges that lie ahead, personalized pain 
management (ie, tailoring treatment based on biopsychosocial mechanisms or characteristics 
identified in individual patients within diagnostic groups) represents an important objective. 
Although no large-scale studies have yet adopted this approach, several smaller studies have 
shown that stratification based on sensory profiles may help predict treatment responses 
among patients with neuropathic pain.5 Thus, there is a need to conduct proof-of-concept 
clinical trials that use novel stratification procedures with the goal of validating individual 
selection criteria to choose therapeutic (pharmacologic and nonpharmacologic) interventions 
that are tailored to treat the individual chronic pain patient.
The accomplishment of Goal 2 will require substantial resources from both public and 
private sectors. A national effort that enables the development of public and private 
consortia, cooperative agreements, databases, and registries is needed. Large population-
based initiatives are required that identify risk determinants and molecular pathways 
associated with chronic pain conditions. At present, only a few public or private initiatives 
show promise in advancing the accomplishment of Goal 2. Two large federally funded 
programs—Orofacial Pain Prospective Evaluation and Risk Assessment (OPPERA) and 
Multi-Disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP)—are the first 
large population studies that seek to identify risk factors and pathways associated with 
complex persistent pain conditions.32,62,65,83 These 2 programs represent a blueprint for the 
development of consortia, cooperative agreements, databases, and registries that will permit 
the successful accomplishment of Goal 2. A national effort involving both public (ie, U.S. 
Department of Health and Human Services) and private (industry) contributions is required 
to accomplish Goal 2 in a manner that impacts our ability to diagnose and manage patients 
suffering from the silent epidemic of chronic pain in America.
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Goal 3: Optimize the Use of and Access to Currently Available Treatments That Are Known 
to Be Effective
A number of pharmacologic and nonpharmacologic treatments are effective for a variety of 
chronic pain conditions. Despite the increased availability of evidence-based guidelines to 
guide management of clinical pain,16–18,43,86 translation of effective treatments to the clinic 
is lacking. Interdisciplinary approaches represent among the most effective treatments for 
chronic pain.35 However, access to interdisciplinary programs is limited because of lack of 
reimbursement.92 Therefore, research that investigates how to not only implement individual 
treatments proven efficacious for chronic pain (ie, physical therapy, psychology) but also 
promote access to interdisciplinary pain treatment programs is essential to improve quality 
of life for the person with pain. This will require studies aimed at identifying the key barriers 
to implementation of therapies that have been shown to be effective but are not commonly 
prescribed. In addition, research is needed to determine effective methods to promote active 
engagement of the individual with pain in their own treatment through exercise and other 
self-management approaches.
Although randomized controlled clinical trials represent the gold standard of clinical 
evidence, their substantial limitations have been cogently presented.9,77,79 Indeed, it is 
widely accepted that even efficacious pain therapies provide clinical benefit to only a 
minority of patients. Enhancements in the methodology and execution of clinical trials for 
pain treatments are needed, including improvement in pain measurement, patient selection, 
study design, and analytic approaches.27,30 Additional research is needed to identify patient 
characteristics that predict responsiveness to specific treatments, which would allow better 
matching between patients and treatments. Further, it has become increasingly clear that the 
use of comparative effectiveness research examining evidence for effectiveness, benefits, 
and harms and the cost of a variety of treatment options can provide a more informed 
decision-making process from both the clinician and patient perspective. For example, 
people with chronic pain conditions often take drugs not just for months but for years, yet 
few clinical trials test for the effects of long-term usage over years. This is particularly true 
for opioids, a class of analgesics that are clearly effective for acute pain but whose benefits 
and adverse effects with chronic use have been the topic of considerable discussion.6,12,96 It 
is critically important to test pain therapies not only for efficacy but also for both therapeutic 
and potential side effects with long-term usage, because such effects may vary over time. 
Although funding of long-term clinical studies is challenging, public-private partnerships 
could be exploited to support such research (see the Barriers section). Moreover, large-scale 
observational studies that exploit existing clinical data sets can provide valuable information 
regarding long-term outcomes. Finally, research is needed to determine whether 
combinations of therapies can produce additive or synergistic effects. As noted above, drug 
combinations may be useful; however, the effectiveness of providing nonpharmacologic 
treatment concurrent with pharmacologic or other medical therapies has received scant 
empirical attention.
Paramount in optimizing the use of and access to effective pain treatments is identifying 
which of the available treatments are effective in the management of chronic pain. 
Unfortunately, the effectiveness and relative costs of various treatments for treating different 
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types of patients are often unclear. Randomized trials of therapies, which maximize the 
internal validity (ie, reduced bias) of treatment comparisons, need to be balanced with real-
world observational studies of therapies as used in clinical practice, which maximize the 
external validity (ie, generalizability) of treatment comparisons. Recently, efforts have 
begun to put in place large-scale open source pain registries to help to address these issues. 
Development and implementation of these pain registries should expand, with the goal of 
broad application and sufficient granularity to enable outcomes and comparative 
effectiveness research on a large scale. Providing this information will enable informed 
decision making on care paths for patients suffering from chronic pain. This work is well 
aligned with the goals of the Patient-Centered Outcomes Research Institute (PCORI), which 
is authorized by Congress to “fund and disseminate research that will provide information 
about the best available evidence to help patients and their health care providers make more 
informed decisions. PCORI’s research is intended to give patients a better understanding of 
the prevention, treatment and care options available, and the science that supports those 
options.”74 Thus, PCORI represents a significant opportunity for funding this type of work, 
but this effort needs wide support by federal and private funders, as all have a vested interest 
in the success of this work.
A related issue is that most of the evidence for efficacy of various treatments is based on 
studies of adult patients, with very little data available on efficacy among pediatric patients. 
This lack of information regarding treatment effects among children is at best a barrier to 
pain care in the pediatric population and at worst may put these patients at risk.36,42,98 Much 
work is therefore needed to test the safety and efficacy of current and emerging therapies for 
treating pain in children.
Goal 4: Understand the Influence of Health Policies and Systems on Pain Treatment
Health policy and systems research is an emerging interdisciplinary field devoted to 
understanding how health systems respond and adapt to health policies, how health policies 
can shape and be shaped by health systems, and how both health policies and health systems 
shape health outcomes.13 Health policy and health systems research can help determine 
optimal contextual factors for implementation of existing treatments and the effectiveness of 
different treatments and implementation strategies. Implementation of the Affordable Care 
Act (ACA) in the United States affords opportunities to study the impact of new health care 
policies and systems of care on pain treatment delivery and outcomes. Several ACA 
initiatives could impact pain care. For example, the ACA designates chronic disease 
management, ostensibly including chronic pain, as a priority with potentially increased 
support for care coordination and self-management training. Also, the ACA mandates parity 
of mental health and substance care with other medical care in expanded Medicaid and state 
exchanges. Mental health comorbidities such as depression and anxiety are more prevalent 
in chronic pain and are predictors of poor outcome to treatment. Further, the ACA 
incentivizes evidence-based treatment and supports collaborative, outcomes-based care, 
which could promote implementation of existing guidelines and clinical trial results into 
chronic pain management. Lastly, the ACA supports expanded use of technology including 
electronic health records and telemedicine,66,80 which should increase access to high quality 
care for chronic pain patients, particularly in more rural parts of the country where pain 
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specialists are not readily available. These ACA features create a need for research aimed at 
determining the effects of these health policy and systems changes not only on pain but also 
on functional status and quality of life. Heath policy and systems research often requires 
fairly large populations to provide the statistical power to test the most meaningful 
outcomes. Because chronic pain treatment and chronic pain–related disability are among the 
largest expenses encountered by workers’ compensation, state and federal employee health 
systems, Medicaid, and private insurers, these systems should be motivated to support the 
study of innovative pain treatment strategies and system changes.
The following research questions should be addressed in the context of health policy and 
systems research. First, what are the most cost-effective models of pain care for specific 
chronic pain conditions? These models could include interdisciplinary treatment centers, 
self-management strategies in clinics, or primary care specialty care collaborations.23,26,53,93 
Second, what factors influence implementation of evidence-based pain treatment? For 
example, how do factors such as availability of pain specialists, third-party reimbursement 
practices, and adoption of systems-wide clinical policies affect delivery and outcomes of 
pain treatment?91 Finally, the impact of technological advances on the availability and 
outcomes of pain treatment needs to be investigated.
Goal 5: Improve Pain Management Through Education Research
In 2012, the International Association for the Study of Pain revised and coordinated 
curriculum guidelines in pain education for multiple disciplines including medicine, nursing, 
pharmacy, psychology, physical therapy, and occupational therapy. Core competencies for 
prelicensure health professional education were recently established34 by consensus of an 
interprofessional group and aligned around the IASP guidelines. The need for investment in 
pain education is substantial as highlighted by the IOM report, which observed that 
preprofessional pain education is quite limited, and a large proportion of primary care 
providers feel unprepared in pain management. A study of Canadian health professions 
found that pain education was low in medical, dental, and pharmacy programs, averaging 
15, 16, and 13 hours, respectively, across the entire curriculum; moderate in nursing, 
occupational, and physical therapy curricula, averaging 31, 28, and 41 hours, respectively; 
and high in veterinary schools, averaging 87 hours in all.99 A detailed study of U.S. and 
Canadian medical schools concluded that U.S. medical schools taught a median of 9 hours 
across the curriculum, whereas Canadian schools provided 19 hours by comparison.67 Thus, 
it is clear that pain education is inadequate in U.S. health profession training programs. 
Beyond this, a multitude of questions remains to be addressed in this field, as addressed 
below.
One of the first pain education research initiatives should be a formal needs assessment and 
task assessment at the level of prelicensure training across all health professions. There 
should be an evidence-based appraisal of all domains essential to pain management. Because 
of the complex nature of pain, the learning tasks of pain-focused education will be complex 
as well. Very little is known about how to most effectively change behaviors and to foster 
more effective clinical outcomes in pain through education. There is tension between the 
current trend away from specifying curricular content and toward competency-based 
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approaches to educational planning, and the trend emphasizing professional, personal, and 
affective development—for example, empathy and compassion—in the effective delivery of 
pain care. Well-developed pain education curricula are needed to prepare health care 
providers who are competent to practice pain management in both the primary care setting 
and advanced tertiary care settings. This will require our institutions of higher education to 
modify curricula and to employ more basic and clinical scientists with backgrounds and 
training in pain research and pain management. Importantly, the outcomes of such 
educational interventions need to be empirically evaluated.
Pain education research needs to be considered within the broader context of health 
profession education in general. Emerging trends in health profession education that are of 
particular relevance to pain education include practice change and methods to produce and 
measure improvements in clinically meaningful outcomes; enhancing knowledge transfer 
and maintaining current and accurate content; and the implementation of patient-centered 
care practices. Moreover, interprofessional and “uni-professional” education must be 
coordinated lest essential profession-specific knowledge and competencies be lost in a focus 
on interprofessional practices. Pain education should take advantage of ongoing 
developments in health profession teaching methodologies, including optimal use of high- 
versus low-fidelity simulations, and innovations in educational assessment (eg, script 
concordance testing, normalized gains analysis, and case-oriented assessment approaches).
Barriers to Transformative Pain Research
The above discussion highlights 5 major research priorities identified by the APS. 
Substantive progress in each of these areas could have tremendous public health impact and 
could produce dramatic improvements in quality of life for tens of millions of chronic pain 
sufferers. This is an aggressive and ambitious research agenda encompassing both 
intermediate and long-term goals. Given the finite resources available to support pain 
research, identifying priorities and timelines to achieve these goals represents an important 
next step in developing the research agenda, but this will require further discussion and input 
from multiple stakeholders. There are several additional factors that serve as barriers to 
progress.
Inadequate Research Funding
It is difficult to overstate the societal impact of pain, yet pain research remains woefully 
underfunded in both public and private sectors. A major investment is needed to improve the 
lives of the 100 million Americans suffering from chronic pain. Although efforts are being 
made to improve federal funding for pain research, these incremental measures are 
inadequate for the magnitude of the problem. Moreover, the current environment in 
Washington generates little optimism that the situation will improve in the near future. A 
paradigm-shifting and transformative realignment of funding priorities and a broader-based 
commitment to fund these priorities in pain research is needed if real progress is to be made. 
This should involve a shift away from classical mortality- and morbidity-based measures of 
disease burden to more modern measures appropriate for chronic disease such as disability-
adjusted life-years and healthy life expectancy.70 This is not simply a need for tweaking 
funding at the NIH. The U.S. Food and Drug Administration, insurers, industry, and private 
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foundations are all needed as partners. This will require greatly expanded advocacy efforts, 
including partnerships between professional organizations and patient advocacy groups, in 
order to educate legislators and policy makers about the societal impact of chronic pain.
Lack of Public Awareness
Despite the fact that chronic pain represents the most prevalent public health condition in the 
United States, there is an alarming lack of public awareness about the magnitude of the 
problem. In a recent poll of U.S. adults commissioned by Research America,1 only 18% of 
respondents identified chronic pain as a major public health problem, whereas far less 
prevalent conditions were much more frequently described as major public health conditions 
(diabetes [52%], drug addiction [47%], alcoholism [37%], and Alzheimer’s disease [34%]). 
This lack of public awareness of chronic pain as a major public health issue not only 
contributes to the continued lack of federal research funding but also helps to explain the 
lack of private and philanthropic support for pain research and treatment. Thus, efforts are 
sorely needed to raise public awareness of both the societal impact of chronic pain and the 
personal suffering of individuals with chronic pain.
Another barrier to enacting the proposed research agenda is the lack of enabling 
infrastructure to support large-scale and transformative pain science. Examples include the 
need for the development of coordinated clinical trial networks and practice-based research 
networks. We will need to support an expansion of interdisciplinary pain research and 
treatment centers and networks (translational medicine centers focused on pain) and, 
importantly, to provide career development infrastructure to expand the number of highly 
trained pain scientists and pain management clinicians who can create novel discoveries and 
translate them into safe and effective new therapies.
Cultural transformation is needed if we are to move forward with the proposed research 
agenda and overcome the identified barriers. As the IOM report stated, “addressing the 
nation’s enormous burden of pain will require a cultural transformation in the way pain is 
understood, assessed, and treated” (p. 1).50 That is, we need a fundamental change in the 
way physicians, legislators, and society view the problem of pain. Chronic pain must 
become a national priority, being recognized as a disease in its own right that produces 
enormous suffering and must be treated aggressively. Effecting this societal change in 
beliefs and attitudes will require significant efforts in education for health care providers, 
patients, legislators, policy makers, and the general public.
Changes in attitude, a refocusing of our efforts and refinement of approaches, improved 
education, the breaking down of barriers, and major investment are needed. These are 
daunting goals, which in the current economic climate might appear unachievable. But this 
is within our reach. Much larger investments in areas of identified urgent need have been 
made, and the results have been nothing short of transformative. The top– down decisions to 
send humans to the moon, declare a war on cancer, decode the human genome, and find a 
way to halt the acquired immune deficiency syndrome epidemic serve as excellent 
examples. Is the daily suffering of 100 million Americans less important? The APS will 
support implementation of this research agenda through increased advocacy efforts; 
continuing and increasing APS funding of pain research; educating policy makers, 
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providers, and the public regarding the societal burden of chronic pain; and forging 
partnerships and collaborations with other organizations and institutions to further promote 
the agenda. As so poignantly stated by an individual with chronic pain, “I wouldn’t wish this 
on anyone, but if researchers [and policy makers] could go through just one day of life as I 
live it, maybe they would understand how devastating this is… There is no hope for people 
with R.S.D. (reflex sympathetic dystrophy)… Please help us” (p. 238; bracketed text 
added).50 Discovery and application of knowledge foster hope, which people with chronic 
pain deserve. We cannot ignore this problem any longer.
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Expenditures for 6 major chronic conditions. Societal cost data (black bars) were derived 
from the following sources: chronic pain,38 heart disease,38 cancer,38 diabetes,38 HIV/
AIDS,49 and Alzheimer’s disease.48 All societal costs were converted to 2010 dollars. NIH 
expenditures (gray bars) are from the NIH categorical spending data providedonnih.gov for 
2012,72 the most recent year available.
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Table 1
Pain Impact Statistics
Pain Impact Total Number or Cost
Number of affected Americans >100,000,000 people
Annual societal costs $635,000,000,000
Annual government expenditures $99,000,000,000
IOM Report: Relieving Pain in America, 2011.50
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Table 2
NIH Expenditures per Affected Person in the United States for 6 Major Chronic Conditions







Abbreviations: HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; NIH, National Institutes of Health; SEER, 
Surveillance, Epidemiology, and End Results Program.
*
Results are based on the following data. NIH expenditures are 2012 data from the NIH website.72 Prevalence data for each condition were 
derived from the following sources: heart disease, 26.5 million89; diabetes, 25.8 million87; HIV/ AIDS, 1.2 million45,46; cancer, 13 million81; 
and chronic pain, 100 million.50 Figures rounded to nearest dollar.
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